• See Also
  1. Molluscum Contagiosum
  • Indications
  1. Molluscum Contagiosum
  • Contraindications
  1. Not FDA approved for age <1 year old
  • Mechanism
  1. Berdazimer Sodium
    1. Topical agent with Antiviral and immunomodulatory activity
    2. Triggers local nitric oxide release
  2. Berdazimer is delivered in a hydrogel polymer
    1. Allows for controlled local release
    2. Hydrogel acts as a proton donor
  • Medications
  1. Available in a carton with 2 tubes (one for Berdazimer Sodium and another for hydrogel)
  2. Expensive (costs $700 per carton in 2025)
  • Dosing
  1. Apply Topical Gel once daily for up to 12 weeks
  2. Avoid wetting region for 1 hour after application
  • Adverse Effects
  1. Well tolerated
    1. Discontinuation rates <3%
  2. Allergic Contact Dermatitis
  3. Local irritant dermatitis
    1. Local irritation, erythema or Pruritus at application site
  • Safety
  1. Unknown safety in pregnancy
  2. Considered safe in Lactation
    1. However, no available safety data for use in Lactation
    2. Avoid application to the Breast or nipple
  • Efficacy
  1. NNT 8 (or 20% of patients) for complete clearance at 12 weeks
  • Resources
  1. Berdazimer (FDA)
    1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217424s000lbl.pdf
  • References
  1. Dabbs (2025) Am Fam Physician 111(3): 263-4 [PubMed]